435 related articles for article (PubMed ID: 30234399)
1. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
3. Advances in targeted therapy for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2018 Feb; 180(4):484-500. PubMed ID: 29193012
[TBL] [Abstract][Full Text] [Related]
4. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.
Hütter-Krönke ML; Fiedler W; Kündgen A; Krauter J; von Lilienfeld-Toal M; Döhner H; Schlenk RF
Haematologica; 2019 Feb; 104(2):e63-e64. PubMed ID: 30171028
[No Abstract] [Full Text] [Related]
5. Updates on targeted therapies for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
[TBL] [Abstract][Full Text] [Related]
6. Approach to patients with primary refractory acute myeloid leukemia.
Orlowski RJ; Mangan JK; Luger SM
Curr Opin Hematol; 2015 Mar; 22(2):97-107. PubMed ID: 25575037
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for older unfit patients with acute myeloid leukemia.
Tang H; Jia S; Bi L; Jia W; Gao G
Future Oncol; 2021 Mar; 17(7):837-851. PubMed ID: 33522289
[TBL] [Abstract][Full Text] [Related]
8. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
9. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
10. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
[TBL] [Abstract][Full Text] [Related]
11. The future of combination treatment with checkpoint inhibitors in melanoma.
Sullivan RJ
Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111
[No Abstract] [Full Text] [Related]
12. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
15. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
16. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
17. Revisiting maintenance therapy in acute myeloid leukemia with novel agents.
Canaani J; Luger SM
Curr Opin Hematol; 2016 Mar; 23(2):175-80. PubMed ID: 26766539
[TBL] [Abstract][Full Text] [Related]
18. Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.
Lazzarotto D; Candoni A; Nadali G; Pavan L; Lessi F; Mosna F; Simeone E; Ventura G; Gherlinzoni F; Semenzato G; Pizzolo G; Fanin R
Eur J Haematol; 2016 Jun; 96(6):586-92. PubMed ID: 26186084
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia: current progress and future directions.
Kantarjian H; Kadia T; DiNardo C; Daver N; Borthakur G; Jabbour E; Garcia-Manero G; Konopleva M; Ravandi F
Blood Cancer J; 2021 Feb; 11(2):41. PubMed ID: 33619261
[TBL] [Abstract][Full Text] [Related]
20. Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
Stratmann J; van Kann E; Rummelt C; Koschade S; Röllig C; Lübbert M; Schaich M; Parmentier S; Sebastian M; Chromik J; Becker von Rose A; Ballo O; Steffen B; Serve H; Brandts C; Shaid S
Leuk Res; 2019 Oct; 85():106192. PubMed ID: 31445469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
